Positive Long-Term Data Shown in Patients with Atopic Dermat

These pivotal trial results from a study in China indicated the potential of this drug as a quarterly treatment for individuals with eczema.

Related Keywords

China , Zheng Wei , Anhui , , Biopharma Holdings , Connect Biopharma Holdings Limited , Connect Biopharma , Biopharma Announces Positive Long Term Data , China Pivotal Trial , Moderate To Severe Atopic , Eczema , Atopic Dermatitis , Rademikibart ,